IM Cannabis Files Shelf Registration for Up to $50M

*TORONTO and GLIL YAM, Israel* — IM Cannabis Corp., a medical cannabis
company with operations in Israel and Germany, filed a shelf registration
statement on Form F-3 with the Securities and Exchange Commission (SEC).
The registration will allow the Company to offer and sell up to an
aggregate of $50 million of its common shares, warrants, units, or a
combination thereof on a registered basis, subject to market conditions,
the Company’s capital needs, and limitations imposed by SEC rules and
applicable securities laws.

The terms of any such offering, including the specific terms and prices of
the Securities, will be determined at the time of such offering and be made
solely by means of the prospectus included in the Registration Statement
and any prospectus supplement that may be filed with the SEC relating to
such offering.

The Shelf Registration does not constitute a commitment by the Company to
sell any specific amount of Securities. Any further offerings under the
Shelf Registration, if made, will be subject to the Company’s discretion
and applicable market conditions.
About IM Cannabis Corp.

IMC (Nasdaq: IMCC) is an international cannabis company that provides
cannabis products to medical patients in Israel and Germany, two of the
largest medical cannabis markets in Europe. The Company leverages a
transnational ecosystem powered by a data-driven approach and a globally
sourced product supply chain. The IMC ecosystem operates in Israel through
its subsidiaries, which imports and distributes cannabis to medical
patients. The Company also operates medical cannabis retail pharmacies,
online platforms, distribution centers, and logistical hubs in Israel that
enable the safe delivery and quality control of IMC products throughout the
entire value chain. In Germany, the IMC ecosystem operates through
Adjupharm GmbH, where it distributes cannabis to pharmacies for medical
cannabis patients.